Advances in treatment of Dyslipidemia
Open accessAbstract
Dyslipidemias have emerged as prevalent disorders among patients, posing significant risks for the development and progression of cardiovascular diseases. These conditions are characterized by elevated levels of total cholesterol (TC), triglycerides (TGs), and low-density lipoprotein cholesterol (LDL-C). This review delves into the current treatment approach, focusing on equalizing these parameters while enhancing the overall quality of life for patients. Through an extensive analysis of clinical trials, we identify disorders that necessitate alternative treatment strategies, notably familial hypercholesterolemia. The primary objective of this review is to consolidate existing information concerning drugs with the potential to revolutionize dyslipidemia management significantly. Among these promising pharmaceuticals, we highlight alirocumab, bempedoic acid, antisense oligonucleotides, angiopoietin-like protein inhibitors, apolipoprotein C-III (APOC3) inhibitors, lomitapide, and cholesterol ester transfer protein (CETP) inhibitors. Our review demonstrates the pivotal roles played by each of these drugs in targeting specific parameters of lipid metabolism. We outline the future landscape of dyslipidemia treatment, envisaging a more tailored and effective therapeutic approach to address this widespread medical concern.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Clinical evidence supports the occurrence of specific adverse effects associated with most lipid-lowering drugs.
“clinical evidence supports the occurrence of specific adverse effects associated with most lipid-lowering drugs (Dybiec et al., 2023).”
From Lactiplantibacillus plantarum N4 ameliorates lipid metabolism and gut microbiota structure in high fat diet-fed rats (2024) · cites this paper as Dybiec et al., 2023
Section 5 reports clinical evidence of specific adverse effects for statins and reports adverse events with alirocumab, volanesorsen, and lomitapide (pages unavailable). This supports the claim for several lipid-lowering drugs, but the review does not establish that such effects occur with most of them; it reports no significant adverse effects for anacetrapib. (LLM, conf=0.83)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961 · see citing works
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300 · see citing works
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185 · see citing works
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854 · see citing works
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487 · see citing works
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634 · cited 1× · see citing works
“There are also papers suggesting a positive cardiovascular effect in post-acute coronary syndrome patients using statins [52].”
BackgroundNordestgaard, B. G., Chapman, M. J., Humphries, S. E., Ginsberg, H. N., Masana, L., Descamps, O. S., Wiklund, O., Hegele, R. A., Raal, F. J., Defesche, J. C., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht273 · Cited by 2,761 · see citing works
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296 · see citing works
Anderson, T. J., Grégoire, J., Pearson, G. J., Barry, A. R., Couture, P., Dawes, M., Francis, G. A., Genest, J., Grover, S., Gupta, M., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.07.510 · Cited by 1,173 · see citing works
European Society of Cardiology: cardiovascular disease statistics 2021
Timmis, A., Vardas, P. E., Townsend, N. P., Torbica, A., Katus, H. A., Smedt, D. D., Gale, C. P., Maggioni, A. P., Petersen, S. E., Huculeci, R., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab892 · Cited by 1,166 · see citing works
A Test in Context: Lipoprotein(a)
Tsimikas, S. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.042 · Cited by 1,137 · cited 1× · see citing works
“It is worth mentioning that there are many controversies related to the determination of Lp(a), because despite many studies, its definitive utility in the diagnosis of dyslipidemia remains unsubstantiated [30].”
BackgroundFerence, B. A., Yoo, W., Alesh, I., Mahajan, N., Mirowska, K. K., Mewada, A., Kahn, J., Afonso, L., Williams, K. A., & Flack, J. M. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.017 · Cited by 898 · see citing works
Global epidemiology of dyslipidaemias
Pirillo, A., Casula, M., Olmastroni, E., Norata, G. D., & Catapano, A. L. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00541-4 · Cited by 882 · see citing works
Pearson, G. J., Thanassoulis, G., Anderson, T. J., Barry, A. R., Couture, P., Dayan, N., Francis, G. A., Genest, J. J., Grégoire, J. C., Grover, S. A., et al. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.03.016 · Cited by 870 · see citing works
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
Ray, K. K., Bays, H. E., Catapano, A. L., Lalwani, N. D., Bloedon, L. T., Sterling, L. R., Robinson, P. L., & Ballantyne, C. M. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1803917 · Cited by 807 · see citing works
Evinacumab for Homozygous Familial Hypercholesterolemia
Raal, F. J., Rosenson, R. S., Reeskamp, L. F., Hovingh, G. K., Kastelein, J. J. P., Rubba, P., Ali, S., Banerjee, P., Chan, K.-C., Gipe, D. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004215 · Cited by 793 · see citing works
Antisense oligonucleotides: the next frontier for treatment of neurological disorders
Rinaldi, C., & Wood, M. J. A. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.148 · Cited by 788 · see citing works
Cuchel, M., Meagher, E. A., du Toit Theron, H., Blom, D. J., Marais, A. D., Hegele, R. A., Averna, M. R., Sirtori, C. R., Shah, P. K., Gaudet, D., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61731-0 · Cited by 744 · see citing works
Sirtori, C. R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.03.002 · Cited by 705 · see citing works
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
Witztum, J. L., Gaudet, D., Freedman, S. D., Alexander, V. J., Digenio, A., Williams, K. R., Yang, Q., Hughes, S. G., Geary, R. S., Arca, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1715944 · Cited by 669 · see citing works
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease
O’Donoghue, M. L., Rosenson, R. S., Gencer, B., López, J. A. G., Lepor, N. E., Baum, S. J., Stout, E., Gaudet, D., Knüsel, B., Kuder, J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2211023 · Cited by 618 · see citing works
Lipid-Related Markers and Cardiovascular Disease Prediction
The Emerging Risk Factors Collaboration (2012) · JAMA · doi:10.1001/jama.2012.6571 · Cited by 539 · see citing works
A Modern Approach to Dyslipidemia
Berberich, A. J., & Hegele, R. A. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab037 · Cited by 502 · see citing works
Nutrition, physical activity, and cardiovascular disease: An update
IGNARRO, L., Balestrieri, M. L., & Claudio Napoli, A. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.06.030 · Cited by 443 · see citing works
Santos, R. D., Gidding, S. S., Hegele, R. A., Cuchel, M., Barter, P. J., Watts, G. F., Baum, S. J., Catapano, A. L., Chapman, M. J., Defesche, J. C., et al. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30041-9 · Cited by 423 · see citing works
Ballantyne, C. M., Banach, M., Mancini, G. B. J., Lepor, N. E., Hanselman, J. C., Zhao, X., & Leiter, L. A. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.002 · Cited by 422 · see citing works
Lamb, Y. N. (2021) · Drugs · doi:10.1007/s40265-021-01473-6 · Cited by 375 · see citing works
Homozygous familial hypercholesterolemia: Current perspectives on diagnosis and treatment
Raal, F. J., & Santos, R. D. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.02.019 · Cited by 349 · see citing works
Cannon, C. P., de Lemos, J. A., Rosenson, R. S., Ballantyne, C. M., Liu, Y., Gao, Q., Palagashvili, T., Alam, S., Mues, K. E., Bhatt, D. L., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.1810 · Cited by 245 · see citing works
Cai, T., Abel, L., Langford, O., Monaghan, G., Aronson, J. K., Stevens, R., Lay-Flurrie, S. L., Koshiaris, C., McManus, R. J., Hobbs, R. F., et al. (2021) · BMJ · doi:10.1136/bmj.n1537 · Cited by 233 · see citing works
Resistance and intolerance to statins
Reiner, Ž. (2014) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.05.009 · Cited by 225 · see citing works
Bays, H. E., Gaudet, D., Weiss, R., Ruiz, J. L., Watts, G. F., Gouni‐Berthold, I., Robinson, J. G., Zhao, J. M., Hanotin, C., & Donahue, S. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1520 · Cited by 219 · see citing works
Tardif, J.-C., Karwatowska-Prokopczuk, E., Amour, E. S., Ballantyne, C. M., Shapiro, M. D., Moriarty, P. M., Baum, S. J., Hurh, E., Bartlett, V. J., Kingsbury, J., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab820 · Cited by 210 · see citing works
Amanat, S., Ghahri, S., Dianatinasab, A., Fararouei, M., & Dianatinasab, M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-1792-1_6 · Cited by 188 · see citing works
Role of Bempedoic Acid in Clinical Practice
Ballantyne, C. M., Bays, H. E., Catapano, A. L., Goldberg, A. C., Ray, K. K., & Saseen, J. J. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07147-5 · Cited by 153 · see citing works
Addressing dyslipidemic risk beyond LDL-cholesterol
Tall, A. R., Thomas, D. G., Gonzalez-Cabodevilla, A. G., & Goldberg, I. J. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148559 · Cited by 150 · see citing works
Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association
Brown, E. E., Sturm, A. C., Cuchel, M., Braun, L. T., Duell, P. B., Underberg, J. A., Jacobson, T. A., & Hegele, R. A. (2020) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2020.04.011 · Cited by 148 · see citing works
Role and mechanism of the action of angiopoietin-like protein ANGPTL4 in plasma lipid metabolism
Kersten, S. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100150 · Cited by 146 · see citing works
Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
Kasichayanula, S., Grover, A., Emery, M. G., Gibbs, M. A., Somaratne, R., Wasserman, S. M., & Gibbs, J. P. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0620-7 · Cited by 135 · see citing works
Secondary Causes of Dyslipidemia
Vodnala, D., Rubenfire, M., & Brook, R. D. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.04.062 · Cited by 123 · see citing works
Regulation of lipoprotein lipase-mediated lipolysis of triglycerides
Basu, D., & Goldberg, I. J. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000676 · Cited by 114 · see citing works
Khetarpal, S. A., Zeng, X., Millar, J. S., Vitali, C., Somasundara, A. V. H., Zanoni, P., Landro, J. A., Barucci, N., Zavadoski, W. J., Sun, Z., et al. (2017) · Nature Medicine · doi:10.1038/nm.4390 · Cited by 109 · see citing works
Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD
Taskinen, M., Packard, C. J., & Borén, J. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0791-9 · Cited by 104 · see citing works
Bempedoic Acid: First Approval
Markham, A. (2020) · Drugs · doi:10.1007/s40265-020-01308-w · Cited by 99 · see citing works
Nurmohamed, N. S., Ditmarsch, M., & Kastelein, J. J. P. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab350 · Cited by 99 · see citing works
Bempedoic Acid: for Whom and When
Ruscica, M., Sirtori, C. R., Carugo, S., Banach, M., & Corsini, A. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01054-2 · Cited by 93 · see citing works
Distribution of lipid levels and prevalence of hyperlipidemia: data from the NHANES 2007–2018
Li, Z., Zhu, G., Chen, G., Luo, M., Liu, X., Chen, Z., & Qian, J. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01721-y · Cited by 89 · see citing works
New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
Kim, K., Ginsberg, H. N., & Choi, S. H. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0198 · Cited by 85 · see citing works
Ginsberg, H. N., & Goldberg, I. J. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.317966 · Cited by 83 · see citing works
Characterizing familial chylomicronemia syndrome: baseline data of the APPROACH study
Blom, D. J., O'Dea, L., Digenio, A., Alexander, V. J., Karwatowska-Prokopczuk, E., Williams, K. R., Hemphill, L., Muñiz-Grijalvo, O., Santos, R. D., Baum, S., et al. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2018.05.013 · Cited by 82 · see citing works
Esan, O., & Wierzbicki, A. S. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s224771 · Cited by 80 · see citing works
D’Erasmo, L., Cefalu, A. B., Noto, D., Giammanco, A., Averna, M. R., Pintus, P., Medde, P., Vigna, G. B., Sirtori, C. R., Calabresi, L., et al. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0531-x · Cited by 76 · see citing works
Underberg, J. A., Cannon, C. P., Larrey, D. G., Makris, L., Blom, D. J., & Phillips, H. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.08.006 · Cited by 76 · see citing works
D’Erasmo, L., Steward, K., Cefalu, A. B., Costanzo, A. D., Boersma, E. H., Bini, S., Arca, M., van Lennep, J. E. R., the Italian and European Working Group on Lomitapide in HoFH, D’Erasmo, L., et al. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab229 · Cited by 71 · see citing works
Hypertension and Dyslipidemia Combined Therapeutic Approaches
Borghi, C., Fogacci, F., Agnoletti, D., & Cicero, A. F. G. (2022) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-022-00507-8 · Cited by 65 · see citing works
Comparison of Current International Guidelines for the Management of Dyslipidemia
Aygün, S., & Tokgözoğlu, L. S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11237249 · Cited by 64 · see citing works
ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets
Akoumianakis, I., Zvintzou, E., Kypreos, K. E., & Filippatos, T. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00914-7 · Cited by 62 · see citing works
Therapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk
Masson, W. M., Lobo, M., Siniawski, D. A., Huerin, M. S., Molinero, G., Valéro, R., & Nogueira, J. P. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.02.005 · Cited by 60 · see citing works
New Therapies for Primary Hyperlipidemia
Aguilar-Salinas, C. A., Gómez-Díaz, R. A., & Corral, P. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab876 · Cited by 60 · see citing works
The Knowns and Unknowns of Contemporary Statin Therapy for Familial Hypercholesterolemia
Pang, J., Chan, D. C., & Watts, G. F. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00884-2 · Cited by 58 · see citing works
New Trends in Dyslipidemia Treatment
Jang, A. Y., Lim, S., Jo, S.-H., Han, S. H., & Koh, K. K. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-1037 · Cited by 56 · see citing works
Taheri, H., Filion, K. B., Windle, S. B., Reynier, P., & Eisenberg, M. J. (2020) · Cardiology · doi:10.1159/000505365 · Cited by 54 · see citing works
He, N., & Ye, H. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-1792-1_5 · Cited by 54 · see citing works
Current Options and Future Perspectives in the Treatment of Dyslipidemia
Muscoli, S., Ifrim, M., Russo, M., Candido, F., Sanseviero, A., Milite, M., Luozzo, M. D., Marchei, M., & Sangiorgi, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164716 · Cited by 52 · see citing works
Antisense Oligonucleotides Targeting Lipoprotein(a)
Langsted, A., & Nordestgaard, B. G. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0792-8 · Cited by 50 · see citing works
Davidson, M. H., Voogt, J. N., Luchoomun, J., Decaris, J., Killion, S., Boban, D., Glass, A., Mohammad, H., Lu, Y., Villegas, D., et al. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.08.006 · Cited by 49 · see citing works
ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis
Mohamed, F., Mansfield, B. S., & Raal, F. J. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01071-1 · Cited by 48 · see citing works
New treatment options for lipid-lowering therapy in subjects with type 2 diabetes
Scicali, R., Pino, A. D., Ferrara, V., Urbano, F., Piro, S., Rabuazzo, A. M., & Purrello, F. (2017) · Acta Diabetologica · doi:10.1007/s00592-017-1089-4 · Cited by 44 · see citing works
Familial Chylomicronemia Syndrome (FCS): Recent Data on Diagnosis and Treatment
Gallo, A., Béliard, S., D’Erasmo, L., & Bruckert, É. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00885-1 · Cited by 44 · see citing works
The effect of CETP inhibitors on new-onset diabetes: a systematic review and meta-analysis
Dangas, K., Navar, A.-M., & Kastelein, J. J. P. (2022) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvac025 · Cited by 44 · see citing works
Blom, D. J., Cuchel, M., Ager, M., & Phillips, H. (2018) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-018-0841-3 · Cited by 43 · see citing works
Nucleic Acid–Based Therapies for Atherosclerosis
Mäkinen, P. I., Ruotsalainen, A., & Ylä‐Herttuala, S. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-0826-2 · Cited by 43 · see citing works
Nohara, A., Otsubo, Y., Yanagi, K., Yoshida, M., Ikewaki, K., Harada‐Shiba, M., & Jurecka, A. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.45708 · Cited by 39 · see citing works
Calcaterra, I. L., Lupoli, R., Minno, A. D., & Minno, M. N. D. D. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13841 · Cited by 38 · see citing works
Alirocumab for the treatment of hypercholesterolemia
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1305354 · Cited by 37 · see citing works
New Therapeutic Approaches in Treatment of Dyslipidaemia—A Narrative Review
Merćep, I., Strikić, D., Slišković, A. M., & Reiner, Ž. (2022) · Pharmaceuticals · doi:10.3390/ph15070839 · Cited by 37 · see citing works
Bempedoic acid for the treatment of dyslipidemia
Marrs, J. C., & Anderson, S. L. (2020) · Drugs in Context · doi:10.7573/dic.2020-6-5 · Cited by 36 · see citing works
Long‐term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia
Larrey, D. G., D’Erasmo, L., O’Brien, S. L., Arca, M., & the Italian Working Group on Lomitapide (2022) · Liver International · doi:10.1111/liv.15497 · Cited by 36 · see citing works
Kosmas, C. E., Bousvarou, M. D., Sourlas, A., Papakonstantinou, E. J., Genao, E. P., Uceta, R. E., & Guzman, E. (2022) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s345072 · Cited by 35 · see citing works
D’Erasmo, L., Gallo, A., Cefalu, A. B., Costanzo, A. D., Saheb, S., Giammanco, A., Averna, M. R., Buonaiuto, A., Iannuzzo, G., Fortunato, G., et al. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01999-8 · Cited by 33 · see citing works
Antisense therapy and emerging applications for the management of dyslipidemia
Toth, P. P. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.08.007 · Cited by 32 · see citing works
Lipoprotein(a) Lowering—From Lipoprotein Apheresis to Antisense Oligonucleotide Approach
Greco, M. F., Sirtori, C. R., Corsini, A., Владиславович, Е. М., Sampietro, T., & Ruscica, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072103 · Cited by 32 · see citing works
Gonna, H., & Ray, K. K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13691 · Cited by 30 · see citing works
Antisense Oligonucleotides for the Treatment of Dyslipidemia
Gouni‐Berthold, I., & Berthold, H. K. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795428830 · Cited by 28 · see citing works
The promising novel therapies for familial hypercholesterolemia
Chen, R., Lin, S., & Chen, X. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24552 · Cited by 28 · see citing works
Spagnuolo, C. M., & Hegele, R. A. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2206015 · Cited by 27 · see citing works
Bempedoic Acid: A Promising Novel Agent for LDL-C Lowering
Agarwala, A., & Goldberg, A. C. (2020) · Future Cardiology · doi:10.2217/fca-2020-0016 · Cited by 24 · see citing works
Efficacy and safety of lomitapide in familial chylomicronaemia syndrome
Cefalu, A. B., D’Erasmo, L., Iannuzzo, G., Noto, D., Giammanco, A., Montali, A., Zambon, A., Forte, F., Suppressa, P., Giannini, S., et al. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.08.017 · Cited by 24 · see citing works
Banerjee, S., & De, A. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.03.016 · Cited by 22 · see citing works
Nutraceuticals in Paediatric Patients with Dyslipidaemia
Banderali, G., Capra, M. E., Viggiano, C., Biasucci, G., & Pederiva, C. (2022) · Nutrients · doi:10.3390/nu14030569 · Cited by 22 · see citing works
Alirocumab: First Global Approval
Markham, A. (2015) · Drugs · doi:10.1007/s40265-015-0469-8 · Cited by 20 · see citing works
Averna, M. R., Cefalu, A. B., Stefanutti, C., Giacomo, S. D., Sirtori, C. R., & Vigna, G. B. (2015) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2015.11.001 · Cited by 20 · see citing works
Evolocumab: A Review in Hyperlipidemia
Keating, G. M. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-015-0153-0 · Cited by 19 · see citing works
Alirocumab: A Review in Hypercholesterolemia
Greig, S. L., & Deeks, E. D. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0166-3 · Cited by 19 · see citing works
Surma, S., Romańczyk, M., & Filipiak, K. J. (2021) · Cardiology Journal · doi:10.5603/cj.a2021.0006 · Cited by 19 · see citing works
Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review
Farnier, M. (2017) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2017.1409115 · Cited by 17 · see citing works
Bempedoic Acid: A New Drug for an Old Problem
Nguyen, D., Du, N., Sulaica, E. M., & Wanat, M. A. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020941083 · Cited by 15 · see citing works
Ácido bempedoico. Mecanismo de acción y propiedades farmacocinéticas y farmacodinámicas
Masana, L., & Plana, N. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.02.012 · Cited by 15 · see citing works
Blom, D. J., Gaudet, D., Hegele, R. A., Patel, D. S., Cegla, J., Kolovou, G. D., & Masana, L. (2022) · Advances in Therapy · doi:10.1007/s12325-021-02031-y · Cited by 15 · see citing works
Evolocumab: Considerations for the Management of Hyperlipidemia
Wiggins, B. S., Senfield, J., Kassahun, H., Lira, A., & Somaratne, R. M. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0720-3 · Cited by 14 · see citing works
D’Erasmo, L., Giammanco, A., Suppressa, P., Pavanello, C., Iannuzzo, G., Costanzo, A. D., Tramontano, D., Minicocci, I., Bini, S., Vogt, A., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.937750 · Cited by 12 · see citing works
Alirocumab for the treatment of hypercholesterolaemia
Pepa, G. D., Bozzetto, L., Annuzzi, G., & Rivellese, A. A. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1318063 · Cited by 11 · see citing works
Inherited metabolic disorders and dyslipidaemia
Sulaiman, R. A. (2019) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2019-205910 · Cited by 11 · see citing works
Liu, J., Shao, P. P., Guiadeen, D., Krikorian, A. D., Sun, W., Deng, Q., Cumiskey, A.-M., Duffy, R. A., Murphy, B. A., Mitra, K., et al. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127668 · Cited by 11 · see citing works
Development of Antisense Oligonucleotide Gapmers for the Treatment of Dyslipidemia and Lipodystrophy
Aslesh, T., & Yokota, T. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0771-8_5 · Cited by 10 · see citing works
Nishida, S., Katsumi, N., & Matsumoto, K. (2020) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.10834 · Cited by 10 · see citing works
A New Modality in Dyslipidemia Treatment: Antisense Oligonucleotide Therapy
Kim, K., & Choi, S. H. (2022) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2022.11.3.250 · Cited by 10 · see citing works
Alirocumab for low-density Lipoprotein Cholesterol Lowering
Roth, E. M. (2018) · Future Cardiology · doi:10.2217/fca-2018-0072 · Cited by 9 · see citing works
Alirocumab (Praluent) to Lower LDL-Cholesterol
(2015) · JAMA · doi:10.1001/jama.2015.11372 · Cited by 9 · see citing works
Bempedoic acid: Everything with a place and purpose
Westerink, J. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487320929779 · Cited by 3 · see citing works
Flagged first, then by citations
1 of the 111 references couldn’t be matched to a known paper.
Research works printed but not linked: 3
- [22]National Institute for Health and Care Exellence Icosapent Ethyl with Statin Therapy for Reducing the Risk of Cardiovascular Events in People with Raised Triglycerides. Technology Appraisal Guidance. Published: 13 July 2022 Available online: https://www.nice.org.uk/guidance/ta805 (accessed on 11 August 2023) 40493729
- [27]Sundjaja J.H. Pandey S. Cholesterol Screening. [Updated 2023 May 1] StatPearls [Internet] StatPearls Publishing Treasure Island, FL, USA 2023 Available online: https://www.ncbi.nlm.nih.gov/books/NBK560894/ (accessed on 11 August 2023) 32809729
- [32]Familial Hypercholesterolaemia: Identification and Management NICE Clinical Guidelines, No. 71 National Institute for Health and Care Excellence (NICE) London, UK 2019 Available online: https://www.ncbi.nlm.nih.gov/books/NBK552672/ (accessed on 11 August 2023) 31944643
Cited by
Sorted by citations
Ma, X., Ren, X., Zhang, X., Wang, G., Liu, H., & Wang, L. (2023) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2023.109501 · Cited by 28 · see citing works
Muszalska, A., Wiecanowska, J., Michałowska, J., Pastusiak, K., Polok, I., Łompieś, K., & Bogdański, P. (2025) · Nutrients · doi:10.3390/nu17050862 · Cited by 26 · see citing works
Młynarska, E., Bojdo, K., Frankenstein, H., Kustosik, N., Mstowska, W., Przybylak, A., Rysz, J., & Franczyk, B. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030887 · Cited by 20 · see citing works
Self-citationDeng, M., Zhang, S., Wu, S., Jiang, Q., Teng, W., Luo, T., Ouyang, Y., Liu, J., & Gu, B. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1390293 · Cited by 15 · see citing works
“Nevertheless, clinical evidence supports the occurrence of specific adverse effects associated with most lipid-lowering drugs (Dybiec et al., 2023).”
BackgroundNechchadi, H., Nadir, Y., Benhssaine, K., Alem, C., Sellam, K., Boulbaroud, S., Berrougui, H., & Ramchoun, M. (2024) · Food Chemistry · doi:10.1016/j.foodchem.2024.140264 · Cited by 14 · see citing works
Abdisa, K. B., Szerdahelyi, E., Molnár, M. A., Friedrich, L. F., Lakner, Z., Koris, A. K., Tóth, A., & Nath, A. (2024) · Biomolecules · doi:10.3390/biom14040478 · Cited by 15 · see citing works
Si, F., Liu, Q., & Yu, J. (2025) · BMC Geriatrics · doi:10.1186/s12877-025-05679-1 · Cited by 11 · see citing works
Zare, P., Bideshki, M. V., Sohrabi, Z., Behzadi, M., & Sartang, M. M. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104057 · Cited by 12 · see citing works
Nițu, E.-T., Jianu, N., Merlan, C., Foica, D., Sbârcea, L., Buda, V. O., Suciu, M., Lombrea, A., & Man, D. E. (2025) · Life · doi:10.3390/life15081185 · Cited by 14 · see citing works
Jamadade, P., Nupur, N., Maharana, K. C., & Singh, S. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01228-0 · Cited by 10 · see citing works
Jyothi, M. V., Ashoka Babu, V. L., Wagh, V. D., Rasheed, A., Dayaramani, R. A., Panigrahy, U. P., Wal, P., & Gunjal, S. D. (2024) · Current Drug Safety · doi:10.2174/0115748863289321240424063819 · Cited by 9 · see citing works
Ultrasensitive Label-Free Biosensor for Triglyceride Detection Based on Exposed-Core Optical Fiber
Zhang, X., Zhou, X., Zhang, Y., Zhao, Y., Nguyen, L. V., Warren-Smith, S. C., & Li, X. (2024) · IEEE Transactions on Instrumentation and Measurement · doi:10.1109/tim.2024.3400334 · Cited by 9 · see citing works
Liang, Z., Chen, S., Zhang, X., Li, J., Guo, W., Ni, L., & Lv, X. (2025) · Foods · doi:10.3390/foods14061054 · Cited by 9 · see citing works
Therapeutic Gene Editing in Dyslipidemias
Zadeh, S. S. T., & Shapiro, M. D. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2508286 · Cited by 8 · see citing works
Behzadi, M., Jowshan, M.-R., Shokri, S., Shahraki, S. H., Amirkhizi, F., Bideshki, M. V., Harooni, J., & Asghari, S. (2025) · Nutrition Journal · doi:10.1186/s12937-025-01158-w · Cited by 8 · see citing works
Wang, J., Qu, J., Ye, M., Feng, R., Hui, X., Yang, X., Jin, J., Tong, Q., Zhang, X., & Wang, Y. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101416 · Cited by 6 · see citing works
Priani, S. E., Chaerunisaa, A. Y., Wilar, G., & Sopyan, I. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s550340 · Cited by 10 · see citing works
Maimaitituersun, G., Jureti, S., Zheng, Y., Zhou, Y., Li, M., Wei, M., Liu, Z., Jin, M., & Fu, Z.-Y. (2025) · PeerJ · doi:10.7717/peerj.19344 · Cited by 5 · see citing works
What are the benefits and drawbacks of statins in carotid artery disease? A perspective review
Said, S., Dardik, A., & Chaar, C. I. O. (2023) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2286011 · Cited by 4 · see citing works
Comorbidity Patterns Among Patients Diagnosed with Sialolithiasis: A Retrospective Analysis
Saleem, R. A., Sukkarieh, H. H., Alkattan, R., Fakhoury, H. M. A., Aljada, A., Theyab, A., & Ababneh, K. T. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113795 · Cited by 3 · see citing works
Apolipoproteins and Lipoproteins in Health and Disease 2.0
Rotllán, N., & Escolá‐Gil, J. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116183 · Cited by 3 · see citing works
Batubo, N. P., Reuben, E., Opusunju, B. H., Ogbu, O. S., & Victor, D. D. (2025) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20250234 · Cited by 2 · see citing works
Ajima, U., Omeni, R. C., Onah, J. O., David, J., & Ehoche, J. O. (2025) · BMC Chemistry · doi:10.1186/s13065-025-01470-w · Cited by 2 · see citing works
Rusanuar, N. D., Aminuddin, A., Hamid, A. A., Kumar, J., Hui, C. K., Mahadi, M. K., & Ugusman, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104619 · Cited by 1 · see citing works
Vijay, A. P., Chakraborty, K., & Pai, A. A. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.107373 · Cited by 1 · see citing works
Management of metabolic dysfunction and cardiovascular risk in patients with MASLD
Danpanichkul, P., Blaney, H. L., Perelli, J., Huerta, P., Idalsoaga, F. J., Arrese, M. A., Arab, J. P., Loomba, R. S., & Díaz, L. A. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.32 · Cited by 1 · see citing works
Stage-dependent dynamics of Apolipoprotein C3 across the spectrum of MASLD
Messer, E. K., Fischer, J., Herta, T., Boehlig, A., Matz‐Soja, M., Tuennemann-Tarr, A., Gaul, S., Laufs, U., & Berg, T. (2026) · PLoS ONE · doi:10.1371/journal.pone.0349666 · Cited by 1 · see citing works
El-Rabbat, K., Zarif, B., Elhafeez, M. A., & Saeed, M. A.-N. (2024) · Research in Cardiovascular Medicine · doi:10.4103/rcm.rcm_24_24 · Cited by 1 · see citing works
Pai, A. A., Chakraborty, K., Raj, A., Kariyil, B. J., Dhara, S., & Anoopraj, R. (2025) · Food Research International · doi:10.1016/j.foodres.2025.116397 · Cited by 1 · see citing works
Bunmee, P., Subhadhirasakul, S., Niyomtham, N., & Siriyong, T. (2025) · Journal of Evidence-Based Integrative Medicine · doi:10.1177/2515690x251391671 · Cited by 1 · see citing works
Relationship between foot and ankle tendinopathies and dyslipidemia: a literature review
Valadares, P. L. O., Araújo, M. A. G. D. S., Silva, I. M. D. S. E., Turini, C. M., Ribeir, A. L. D. A., Nunes, A. C. F., & Júnior, E. Á. S. (2024) · Journal of the Foot & Ankle · doi:10.30795/jfootankle.2024.v18.1788
Relationship Between Dyslipidemia and Alzheimer’s Disease
Bolayırlı, M., & Kücür, M. (2024) · doi:10.69860/nobel.9786053359166.12
Batubo, N. P., Reuben, E., Opusunju, B. H., Ogbu, O. S., & Victor, D. D. (2025) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20250659
Wu, T., Zhang, L., Tian, J., Lu, Y., Yang, Y. F., Yang, X., Jin, P., Gu, Y., Wang, X., & Lin, Y. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02625-3
Exploring the Role of Propolis on Lipid Profile of Wistar Rats with Induced Dyslipidemia
Radhiyanti, P. T., Immanuela, K., Goenawan, H., Sylviana, N., Lesmana, R., Fatimah, S. N., & Zulhendri, F. (2025) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/3186
Recent Advances in Medications for Reducing Lipid Levels
Hu, X., Jia, X. T., & Wang, X. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001020
Арманович, А. А., Kaktursky, L. V., Urazova, O. I., Трофименко, А. И., Sukiasyan, L. M., Коган, Е. А., Демура, Т. А., & Вачиковна, П. Н. (2025) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.20538/1682-0363-2025-2-124-140
Pharmacological targets in metabolic syndrome related dyslipidemia
Cariño‐Cortés, R., Manuel, M.-P. V., Ortiz, M. I., Luis, J.-S., Fernández‐Martínez, E., & Fernanda, V.-C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00005-6
Zhang, Y., Yang, S., Han, F., Fu, H., Wang, C., & Ma, Y. (2026) · Critical Public Health · doi:10.1080/09581596.2025.2607271
Chen, Z., Wang, Y., & Chen, B. (2026) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-026-03855-x
Kumaresan, V., Joshi, S. S., Shetty, Y. C., & Doke, M. T. (2026) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20260432
Al-Hetar, M. A. M. Y., Wahab, N. A., Al-Shawky, S., Al-Matary, A. M., Senan, D. A. M., Alezzy, M. E., AlHetar, M. M., & Asaber, A. M. (2026) · Cureus · doi:10.7759/cureus.105450
Дунаєва, І., Kryvoshapka, О. V., Pautina, O. I., Doroshenko, O. M., Шаповал, О. М., Chorna, N., & Руда, Н. Г. (2026) · Bulletin of Problems Biology and Medicine · doi:10.29254/2077-4214-2026-1-180-61-72
Elkina, A. Y., Shvarts, Y. G., Kiselev, A. R., & Акимова, Н. С. (2026) · Current Hypertension Reviews · doi:10.2174/0115734021428732251226052716
Jia, Z., Li, H., Lu, Y., Shi, C., wang, Y., Chen, X., Zhang, W., Lu, D., Cao, Y., Wang, P., et al. (2026) · Food Chemistry · doi:10.1016/j.foodchem.2026.149706
Ahmed, T., Nath, A., Jahan, N., Hoque, N., Jahan, M. K., Kaniz, M. S., Dutta, S., Saha, S., Haque, M. A., & Bowden, R. G. (2026) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph23050662
Lorensia, A., Muntu, C. M., Budipramana, K., Jalmav, M. M. A., & Diputra, I. W. Y. (2026) · IJMT Indonesian Journal of Midwifery Today · doi:10.30587/ijmt.v5i2.11629
Hepatic steatosis: A pandemic disease causing serious secondary diseases
Canbay, A., Figge, A., Patsalis, P., Baars, T., Özcürümez, M. K., & Götze, O. (2026) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2026.0074
Maștaleru, A., Leon, M. M., Abdulan, I. M., Popescu, G., Roca, M., Costache, A. D., Cumpăt, C. M., Rusu, C., & Mitu, F. (2026) · Current Psychology · doi:10.1007/s12144-026-09730-1
Pugazhenthi, D. P., Karunanithi, S. S. M., Murugavel, D., Krishnan, K., & Shanmugasundaram, P. (2026) · Journal of Applied Pharmaceutical Science · doi:10.1177/22313354261461001
Javed, S., Hassan, F., Aslam, B., & Ijaz, M. (2026) · Asian Pacific Journal of Tropical Biomedicine · doi:10.4103/apjtb.apjtb_197_26
Srivastava, R. A. K. (2026) · Cells · doi:10.3390/cells15171575
Zorger, A.-M., Muth, A., Shokraee, K., Olfati, S., Monsef, I., Franco, J. V. A., & Skoetz, N. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016382
Hodrob, T., Saad, R. J., Hamdy, A., Alheneedy, M. S., Elsayed, A. M. S. A., Ghazy, E., & Ayesh, H. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70353
Apolipoprotein A (ApoA) in Cardiovascular Disorders: Connections and Insights
Hassanein, A., Rajha, H. E., Hamid, M. A., Hashem, I. E.-A., Al-Saady, R., & Pedersen, S. (2026) · Angiology · doi:10.1177/00033197261491118
- Authors
- Dybiec, J., Baran, W., Dąbek, B., Fularski, P., Młynarska, E., Radzioch, E., Rysz, J., & Franczyk, B.
- Affiliations
- Medical University of Lodz (PL)
- Corresponding author
- Młynarska, Ewelina
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-08-27
- Volume
- 24
- Issue
- 17
- Pages
- 13288
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10488025
- OpenAlex
- W4386222220
- Cited by
- 55
- References
- 111
- Citations by year
- 2026: 19 · 2025: 23 · 2024: 11 · 2023: 2
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Keywords
- dyslipidemia, lipid-lowering therapy, PCSK9 inhibitors, alirocumab, bempedoic acid, antisense oligonucleotides, lomitapide, CETP inhibitors, familial hypercholesterolemia, cardiovascular risk, LDL cholesterol, triglycerides, total cholesterol
- MeSH terms
- Angiopoietin-like Proteins, Humans, Cholesterol, LDL, Quality of Life, Dyslipidemias, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
